98%
921
2 minutes
20
This study introduces an efficient on-column refolding and purification method for preparing nanobodies (Nbs) expressed as inclusion bodies and fusion proteins. The HisTrap FF system was successfully employed for the purification of the fusion protein FN1-ΔI-CM-2D5. The intein ΔI-CM cleavage activity was activated at 42 °C, followed by incubation for 4 h. Leveraging the remarkable thermal stability of Nbs, 2D5 was further purified through heat treatment at 80 °C for 1h. This method yielded up to 107.2 mg of pure 2D5 with a purity of 99.2 % from just 1L of bacterial culture grown in a shaker flask. Furthermore, this approach successfully restored native secondary structure and affinity of 2D5. Additionally, the platform was effectively applied to the refolding and purification of a polystyrene-binding nanobody (B2), which exhibited limited expression in the periplasmic and cytoplasmic spaces of E. coli. This endeavor resulted in the isolation of 53.2 mg of pure B2 Nb with a purity exceeding 99.5 % from the same volume of bacterial culture. Significantly, this approach restored the native secondary structure of the Nbs, highlighting its potential for addressing challenges associated with expressing complex Nbs in E. coli. Overall, this innovative platform provides a scientifically rigorous and reproducible method for the efficient preparation of Nbs, offering a valuable tool for antibody research and development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jchromb.2024.124279 | DOI Listing |
Protein Expr Purif
August 2025
Microbial and Viral Platforms (MVP), WuXi Biologics, 291 Fucheng Road, Hangzhou, 311106, China. Electronic address:
Human interleukin-2 (hIL-2) serves as a crucial cytokine in the treatment of cancer and autoimmune disorders. Nevertheless, the advancement of research and clinical applications involving this cytokine has been hindered by the constraints associated with the production of recombinant human interleukin-2 (rhIL-2). This study presents a scalable and robust purification protocol for rhIL-2 derived from inclusion bodies (IBs) in Escherichia coli.
View Article and Find Full Text PDFBio Protoc
August 2025
Institute of Health Sciences and Technology (IHST), Institutes of Physical Sciences and Information Technology, Anhui University, Hefei, China.
The Sox (SRY-related HMG-box) protein family plays a crucial role in cellular differentiation, development, and gene regulation, with the HMG (high-mobility group) domain responsible for DNA binding and transcriptional regulation. Proteins in the SOX gene family contain an HMG domain that shares 50% homology with the HMG domain of the sex-determining factor SRY gene. The SOX gene family comprises 30 proteins, which are classified into 10 groups (A-H).
View Article and Find Full Text PDFBio Protoc
August 2025
Department of Structural Biology, Stanford University, Stanford, CA, USA.
Zinc-finger (ZF) arrays are compact, sequence-specific polynucleotide-binding domains, which have been used to target the delivery of diverse effector domains, enabling applications such as gene identification, localization, regulation, and editing. To facilitate in vitro applications of ZF arrays, we have developed a general method for their expression and purification. Here, we describe a protocol involving two chromatographic steps that yields homogeneous and functional ZF arrays in milligram quantities.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
Jiangsu Key Laboratory of Brain Disease and Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Medical University, Xuzhou 221004, China. Electronic address:
Recovery of bioactive proteins from insoluble inclusion bodies (IB) is a critical challenge when purifying recombinant proteins expressed in E. coli. One practical solution is to enhance the renaturability or refolding capability of the target protein after the insoluble proteins are solubilized with denaturants such as urea.
View Article and Find Full Text PDFRes Pharm Sci
June 2025
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Background And Purpose: Single-chain variable fragments (scFvs) offer advantages over full-length monoclonal antibodies in cancer therapy, including reduced size, lower production costs, and easier handling. However, ) often leads to the formation and aggregation of inclusion bodies (IBs). This study aimed to optimize the expression and purification of an anti-CD22 scFv (CD22-scFv) in and evaluate its functional properties.
View Article and Find Full Text PDF